RxDoctor Payments Data

Lawrence Sigler, MD

Urology · Bronxville, NYNPI 1063581874

Payments from drug & device makers

$4,903in general payments, 2019–2025

Across 209 payments — averaging $23.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Sumitomo Pharma America, Inc.$710
  • Astellas Pharma US Inc$574
  • Bayer$525
  • Tolmar, Inc.$250
  • Antares Pharma, Inc.$249
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,72896%
  • Education$1754%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,903 in reported general payments places this provider in the 60th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$461,503
Medicare patients
822
Services billed
8,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide75$1,148,392
GemtesaVibegron141$99,498
MyrbetriqMirabegron100$83,203
Solifenacin Succinate272$17,323
Tamsulosin Hcl906$16,460
Mirabegron ErMirabegron13$10,612
Alfuzosin Hcl ErAlfuzosin Hcl334$7,016
Tolterodine Tartrate ErTolterodine Tartrate49$6,548
Finasteride459$6,452
Potassium Citrate ErPotassium Citrate48$6,298
Dutasteride150$6,279
Doxazosin Mesylate257$4,720
Methenamine Hippurate27$2,858
Tadalafil23$2,361
Oxybutynin Chloride ErOxybutynin Chloride100$2,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$574$1,231,595175 claims
Sumitomo Pharma America, Inc.Gemtesa$710$99,498141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 952 urology providers in New York.

Other urology in Bronxville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →